Boster Biological Technology advances biotechnology research with its cutting-edge multiplex ELISA service, delivering ...

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

Charles River Laboratories International, Inc. and Akron Bio ("Akron"), a leading supplier of critical materials and services for advanced therapies, today announced the integration of Akron's Closed ...

primarily revolving around the promising commercial prospects of Cytokinetics’ drug pipeline. The company’s strategic focus is on aficamten, which is anticipated to gain approval and be ...

The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale. With more than $1 billion raised last year, Blum is preparing ...

subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. ...

He, H.J., Cen, X.H., Liang, Y.J., Zhong, J.M., Deng, J.H. and Jiang, Y.J. (2025) Progress in the Regulation of Lipid Metabolism by the Orphan Nuclear Receptor Nur77. Journal of Biosciences and ...